Global Radiopharmaceuticals Market 2023-2029

Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases. Radiopharmaceuticals may be given to the patient in several different ways. For example, they may be given by mouth, given by injection, or placed into the eye or into the bladder. The global radiopharmaceuticals market is projected to rise by USD 7.5 billion by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 9.7 percent during the forecast period.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global radiopharmaceuticals market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, production method, application, end user, and region. The global market for radiopharmaceuticals can be segmented by product: diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals. According to the research, the diagnostic radiopharmaceuticals segment had the largest share in the global radiopharmaceuticals market. Radiopharmaceuticals market is further segmented by production method: nuclear reactor, cyclotron, generator. In 2022, the nuclear reactor segment made up the largest share of revenue generated by the radiopharmaceuticals market. Based on application, the radiopharmaceuticals market is segmented into: cardiovascular diseases, neurological disorders, oncology, others. Among these, the oncology segment was accounted for the highest revenue generator in 2022. On the basis of end user, the radiopharmaceuticals market also can be divided into: diagnostic centers, hospitals, research institutes, others. The hospitals segment captured the largest share of the market in 2022. Radiopharmaceuticals market by region is categorized into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America.

The diagnostic radiopharmaceuticals market is further segmented into SPECT radiopharmaceuticals, PET radiopharmaceuticals, others. The latest analysis indicates that the SPECT radiopharmaceuticals segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Furthermore, the therapeutic radiopharmaceuticals market has been categorized into beta emitters, alpha emitters, brachytherapy seeds, others. Globally, the beta emitters segment made up the largest share of the radiopharmaceuticals market.

Market Segmentation
By product: diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals
By production method: nuclear reactor, cyclotron, generator
By application: cardiovascular diseases, neurological disorders, oncology, others
By end user: diagnostic centers, hospitals, research institutes, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report explores the recent developments and profiles of key vendors in the Global Radiopharmaceuticals Market, including Advanced Accelerator Applications S.A. (Novartis AG), Australian Nuclear Science and Technology Organisation (ANSTO), Bayer AG, Bracco S.p.A., Cardinal Health, Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, ECZACIBASI-MONROL Nuclear Products Co., Eli Lilly and Company, GE Healthcare, IBA Radiopharma Solutions (Ion Beam Applications SA), IRE - IRE ELiT, Jubilant Life Sciences Ltd., Lantheus Holdings, Inc., Navidea Biopharmaceutical, Inc., Nordion, Inc., NTP Radioisotopes SOC Ltd., Siemens Healthineers AG, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global radiopharmaceuticals market.
To classify and forecast the global radiopharmaceuticals market based on product, production method, application, end user, region.
To identify drivers and challenges for the global radiopharmaceuticals market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global radiopharmaceuticals market.
To identify and analyze the profile of leading players operating in the global radiopharmaceuticals market.

Why Choose This Report
Gain a reliable outlook of the global radiopharmaceuticals market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
PART 1. INTRODUCTION
Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
Introduction
Drivers
Restraints
PART 5. MARKET BREAKDOWN BY PRODUCT
Diagnostic radiopharmaceuticals
Therapeutic radiopharmaceuticals
PART 6. MARKET BREAKDOWN BY PRODUCTION METHOD
Nuclear reactor
Cyclotron
Generator
PART 7. MARKET BREAKDOWN BY APPLICATION
Cardiovascular diseases
Neurological disorders
Oncology
Others
PART 8. MARKET BREAKDOWN BY END USER
Diagnostic centers
Hospitals
Research institutes
Others
PART 9. MARKET BREAKDOWN BY REGION
North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America
PART 10. KEY COMPANIES
Advanced Accelerator Applications S.A. (Novartis AG)
Australian Nuclear Science and Technology Organisation (ANSTO)
Bayer AG
Bracco S.p.A.
Cardinal Health, Inc.
Eckert & Ziegler Strahlen- und Medizintechnik AG
ECZACIBASI-MONROL Nuclear Products Co.
Eli Lilly and Company
GE Healthcare
IBA Radiopharma Solutions (Ion Beam Applications SA)
IRE - IRE ELiT
Jubilant Life Sciences Ltd.
Lantheus Holdings, Inc.
Navidea Biopharmaceutical, Inc.
Nordion, Inc.
NTP Radioisotopes SOC Ltd.
Siemens Healthineers AG
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER

2024 Global Hepatitis Diagnostic Testing Markers Supplier Shares and Strategies Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals Blood Banks Commercial Labs POC Locations

2024 Global Hepatitis Diagnostic Testing for 10 Markers: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals, Blood Banks, Commercial Labs, POC Locations The

USD 7500 View Report

2024 Global PSA Testing Market Supplier Shares and Strategies Volume and Sales Segment Forecasts Emerging Opportunities

2024 Global PSA Testing Market: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Opportunities This unique report from provides information and analysis not available from any

USD 2450 View Report

Global Non-Oncology Radiopharmaceuticals Market Outlook

The non-Oncology Radiopharmaceuticals Market is anticipated to grow with a value CAGR of 9.6% over 2019-2028. According to a study published by Insure Insights on the Non-Oncology Radiopharmaceuticals, it suggests

USD 3950 View Report

Global SPECT Radiopharmaceuticals Market Research Report 2021-2025

In the context of China-US trade war and COVID-19 epidemic, it will have a big influence on this market. SPECT Radiopharmaceuticals Report by Material, Application, and Geography Global Forecast

USD 3200 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available